No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY SCANDINAVIA&BALTICS

Nordic biotech company lands €37M seed funding to advance anti-fibrotic drug into clinical trials

Arctic Startupby Arctic Startup
April 15, 2025
Reading Time: 6 mins read
in SCANDINAVIA&BALTICS, VENTURE CAPITAL
Share on FacebookShare on Twitter
– Advertisement –

Tribune Therapeutics, a Stockholm- and Oslo-based biotech company developing therapies for fibrotic diseases, has secured €37 million in seed and Series A funding. The Series A round, totaling €23 million, was led by LifeArc Ventures and joined by Industrifonden and Investinor, alongside existing investors Novo Holdings, HealthCap, Innovestor’s Life Science Fund, and Inven2. The funding will support the clinical development of TRX-44, Tribune’s lead candidate targeting the CCN protein family, with initial focus on idiopathic pulmonary fibrosis (IPF). The company aims to address fibrotic conditions by targeting key proteins involved in scar tissue formation, a different approach from current treatments that focus primarily on inflammation or growth factors. In addition to advancing TRX-44 into trials, Tribune will continue developing other candidates targeting downstream regulators of fibrosis.

Tribune Therapeutics develops therapeutics for fibrotic diseases. The company focuses on targeting the CCN family of proteins, which play a central role in scar tissue formation. Its lead candidate, TRX-44, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and is designed to mimic the activity of the endogenous protein CCN5. Tribune’s research approach involves modulating downstream regulators of fibrosis with the aim of addressing fibrotic processes across different tissues.

“Tribune was founded on groundbreaking discoveries about the underlying drivers of fibrosis. From the beginning, it was clear that these discoveries had far-reaching therapeutic implications,” said Georg Vo Beiske, PharmD, Tribune Chief Executive Officer and HealthCap Venture Partner. “Advancing our programs towards the clinic with the backing of such a strong and prestigious investor group further increases our confidence in our innovative approach to treat fibrotic diseases, many of which are fatal.”

Current standard-of-care for the millions of patients with fibrotic diseases of the lung, kidney, liver and other tissue types is limited to managing symptoms or moderately slowing disease progression by targeting inflammatory mediators or growth factors. To create broadly applicable disease-modifying therapies, Tribune is instead targeting downstream, tissue-agnostic gatekeepers of scar formation and tissue remodeling, including the CCN family of proteins.

The company’s lead program, TRX-44, is currently in development for the treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF), a chronic fibrotic lung disease that leads to respiratory failure and death within three to five years of diagnosis. The Series A financing will prepare TRX-44 to begin clinical trials and will advance additional programs targeting the CCN protein family.

TRX-44 prevents scar formation by mimicking the structure and function of CCN5. CCN5 is an endogenous protein that naturally blocks the pro-fibrotic effects of other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to the fibrotic pathology. This approach is an evolution from blocking individual CCN proteins and their upstream activator, TGF-beta, and has the potential to combat a broader set of fibrotic diseases while avoiding the toxic side effects that have hampered the development of less targeted approaches.

“Fibrotic diseases like IPF are devastating and often terminal,” said João Ribas, PhD, Principal of Novo Holdings. “Tribune’s approach exploits the biology of CCNs to shut down a key pro-fibrotic pathway, and is the kind of novel strategy that can meaningfully impact the treatment of multiple fibrotic indications.”


“After reviewing the preclinical data for TRX-44 and meeting the impressive team behind it, we recognized the potential transformational impact of this strategy,” said Chris Baker, PhD, Investment Principal at LifeArc Ventures. “Tribune has the opportunity to pioneer a new approach to the treatment of fibrotic diseases that could make debilitating conditions like IPF manageable, improving quality of life and giving new hope to thousands of patients diagnosed each year.”

In conjunction with the financing, LifeArc’s Baker and Industrifonden’s Jonathan Ilicki, MD, MBA, will join Tribune’s board.

Click to read more funding news.

– Advertisement –

Read the orginal article: https://arcticstartup.com/tribune-therapeutics-raises-e37m-seed/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

German FinTech startup Circula secures €15 million as it cuts expense admin by 80%

May 8, 2025
FRANCE

EU unlocks €500m to become a “magnet for researchers”

May 8, 2025
UK&IRELAND

British startup Doubleword raises €10.6 million to make self-hosted AI inference effortless for enterprises

May 8, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

UK Fintech Marshmallow Secures $90 Million in Funding at a Valuation of $2 Billion

Data center proposed for Vancouver Island, Canada

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart